Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03328897
Other study ID # CIGE025E2305
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date April 26, 2017
Est. completion date September 24, 2019

Study information

Verified date October 2020
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to demonstrate the efficacy and safety of omalizumab, compared with placebo, as an add-on to H1 antihistamines (H1AH) therapy in adult patients suffering from Chronic Spontaneous Urticaria (CSU) who remained symptomatic despite H1AH therapy.


Description:

This was a randomized, multicenteric, double-blinded, placebo-controlled, parallel-group study to evaluate the efficacy and safety of omalizumab as an add-on therapy for the treatment of patients of refractory CSU who remained symptomatic despite approved-dosed H1AH treatment. The study consisted of three distinct epochs over 24 weeks: Screening epoch (Day -28 to Day -1), Randomized treatment epoch (Day 1 to Week 12) and Post-treatment follow-up epoch (Week 12 to Week 20). Patients were randomized into three treatment groups (omalizumab 300 mg s.c. omalizumab 150 mg s.c. and placebo) in a 2:2:1 ratio, stratified by latent tuberculosis (TB) status at Baseline (Yes/No). On Day 1, eligible patients were randomly assigned to receive omalizumab (150 mg or 300 mg) or placebo by subcutaneous (s.c.) injection every 4 weeks (on Day 1, Week 4, and Week 8) during the 12-week double-blind randomized-treatment epoch. Patients visited the study center at 4-week intervals. Patients were instructed to stay on the same CSU H1AH treatment at stable dose that they were using during the pre-randomization period during the randomized treatment epoch. They were allowed to use diphenhydramine as rescue medication during all epochs. The last dose of the study drug during the randomized-treatment epoch was administered at Week 8 study visit, however, the last assessment was done at Week 12. After the completion of the 12-week randomized-treatment epoch, all patients entered an 8-week post-treatment follow-up epoch.


Recruitment information / eligibility

Status Completed
Enrollment 418
Est. completion date September 24, 2019
Est. primary completion date July 23, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Main Inclusion Criteria: - Symptomatic CSU patients with CSU diagnosis for at least 6 months. - Patients must have been on an approved dose of an H1AH for CSU for at least the 3 consecutive days immediately prior to the Day -14 screening visit - Patients must have documented current use on the day of the initial screening visit Main Exclusion Criteria - Clearly defined underlying etiology for chronic urticarias other than CSU (main manifestation being physical urticaria) - Other skin disease associated with itch Urticarial vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary or acquired angioedema, lymphoma, leukemia, or generalized cancer

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Omalizumab
injection of 150mg or 300 mg
Placebo
Injection of placebo

Locations

Country Name City State
China Novartis Investigative Site Beijing Beijing
China Novartis Investigative Site Beijing
China Novartis Investigative Site Beijing
China Novartis Investigative Site Beijing
China Novartis Investigative Site Changsha Hunan
China Novartis Investigative Site Chengdu Sichuan
China Novartis Investigative Site Chongqing
China Novartis Investigative Site Chongqing
China Novartis Investigative Site Fuzhou Fujian
China Novartis Investigative Site Guangzhou Guangdong
China Novartis Investigative Site Guangzhou
China Novartis Investigative Site Hangzhou Zhejiang
China Novartis Investigative Site Hangzhou Zhejiang
China Novartis Investigative Site Hangzhou Zhejiang
China Novartis Investigative Site Harbin Heilongjiang
China Novartis Investigative Site Nanjing
China Novartis Investigative Site Nanjing Jiangsu
China Novartis Investigative Site Nanning Guangxi
China Novartis Investigative Site Shanghai
China Novartis Investigative Site Shanghai
China Novartis Investigative Site Shanghai
China Novartis Investigative Site Shenyang Liaoning
China Novartis Investigative Site Suzhou Jiangsu
China Novartis Investigative Site Urumqi Xinjiang
China Novartis Investigative Site Wuhan Hubei
China Novartis Investigative Site Wuhan Hubei
China Novartis Investigative Site Wuxi Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline of the Itch Severity Score (ISS7) Score After 12 Weeks of Treatment The severity of the itch was recorded by the patient twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). Baseline ISS7 was calculated 7 days prior to the first treatment date. A weekly score (ISS7) was derived by adding up the average daily scores of the seven days preceding the visit. The possible range of the weekly score was therefore 0 to 21, where 0 is the best score and 21 is the worst score. The complete itch response was defined as ISS7 = 0.
Itch (Pruritus) Severity Score Scale:
0 = None
= Mild (minimal awareness, easily tolerated)
= Moderate (definite awareness, bothersome but tolerable)
= Severe (difficult to tolerate)
Baseline, Week 12
Secondary Change From Baseline of Urticaria Activity Score (UAS7) After 12 Weeks of Treatment UAS7 is the sum of the HSS7 and the ISS7 scores. The possible range of the weekly UAS7 score is 0 to 42. A higher urticaria activity score indicates more severe symptoms. A negative change score from baseline indicates improvement. Baseline, Week 12
Secondary Change From Baseline of Number of Hives Score (NHS7) After 12 Weeks of Treatment Hives Severity Score (HSS), defined by number of hives, were recorded by the patient twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). A weekly number of hives score (NHS7) was derived by adding up the average daily scores of the seven days preceding the visit. The possible range of the weekly score was therefore 0 to 21. The complete hives response was defined as NHS7 = 0.
Hives Severity Score scale:
0 - None
Mild (1-6 hives/12 hours)
Moderate (7-12 hives/12 hours)
Severe (>12 hives/12 hours)
Baseline, Week 12
Secondary Percentage of Patients With UAS7=6 at Week 12 UAS7 is the sum of the HSS7 and the ISS7 scores. The possible range of the weekly UAS7 score is 0 to 42. A higher urticaria activity score indicates more severe symptoms. A negative change score from baseline indicates improvement. Week 12 responders were defined as patients who achieved an absolute UAS7 = 6 at Week 12. A patient with missing data at Week 12 was imputed as a responder if the patient was a responder at Week 10 and Week 11, otherwise as a non-responder. Week 12
Secondary Percentage of Complete Responders (UAS7 = 0) at Week 12 UAS7 is the sum of the HSS7 and the ISS7 scores. The possible range of the weekly UAS7 score is 0 to 42. A higher urticaria activity score indicates more severe symptoms. A negative change score from baseline indicates improvement. Complete responders are defined as participants who achieved UAS7 = 0. Week 12
Secondary Percentage of Patients With ISS7 Minimally Important Difference (MID) at Week 12 The severity of the itch was recorded by the patient twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). Baseline ISS7 was calculated 7 days prior to the first treatment date. A weekly score (ISS7) was derived by adding up the average daily scores of the seven days preceding the visit. The possible range of the weekly score was therefore 0 to 21, where 0 is the best score and 21 is the worst score. The complete itch response was defined as ISS7 = 0.
Itch (Pruritus) Severity Score Scale:
0 = None
= Mild (minimal awareness, easily tolerated)
= Moderate (definite awareness, bothersome but tolerable)
= Severe (difficult to tolerate)
The ISS7 MID response was defined as a reduction from Baseline in ISS7 of = 5 points.
Week 12
Secondary Change From Baseline of Dermatology Life Quality Index (DLQI) Score After 12 Weeks of Treatment Dermatology life quality index (DLQI) is a 10-item dermatology- specific health-related quality of life measure. Patients rated their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives. An overall score was calculated as well as separate scores for the following domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, treatment. Each domain had 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. Week 12
Secondary Time to ISS7 MID Response by Week 12 The ISS7 MID response was defined as a reduction from Baseline in ISS7 of = 5 points. Time to ISS7 MID response was the time (in weeks) from the date of the first dose to the date where ISS7 MID response was first achieved during Week 1 to Week 12. 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06077773 - Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria Phase 2
Completed NCT04538794 - A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria Phase 1
Completed NCT01803763 - Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients Phase 2/Phase 3
Recruiting NCT05298215 - A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria Phase 2
Terminated NCT04612725 - A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO) Phase 2
Terminated NCT05528861 - A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria Phase 2
Completed NCT04109313 - An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU Phase 2
Completed NCT03580356 - A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. Phase 3
Completed NCT03580369 - A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines Phase 3
Completed NCT05030311 - A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines Phase 3
Recruiting NCT06162728 - Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU) Phase 1/Phase 2
Completed NCT05107115 - Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine Phase 2
Recruiting NCT06042478 - A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients. Phase 3
Terminated NCT04159701 - A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria Phase 2
Completed NCT03749135 - Dupilumab in Chronic Spontaneous Urticaria Phase 2
Not yet recruiting NCT06396026 - A Study of Efficacy and Safety of TLL-018 in CSU Participants Phase 3
Completed NCT02649218 - A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients Phase 2
Active, not recruiting NCT05368285 - A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria Phase 2
Completed NCT05373355 - Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria. Phase 1
Not yet recruiting NCT06365879 - To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria Phase 3